Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Seiler

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
World Journal of Urology|January 12, 2017
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive reviewAtiqullah Aziz, Jakub Dobruch, Kees Hendricksen, et al.
The Journal of Urology|February 3, 2021
Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center StudyMarc A Furrer, Bernhard Kiss, Urs E Studer, et al.
Urologic Oncology|November 27, 2022
25 years International Bladder Cancer Network (IBCN): The past, the present, and the futureLars Dyrskjøt, Antonia Vlahou, Peter C Black, et al.
Urologic Oncology|June 4, 2021
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinomaTilman Todenhöfer, Ewan A Gibb, Roland Seiler, et al.
Oncotarget|February 20, 2016
Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2Melissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
Urologic Oncology|January 26, 2023
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1Patrick J Hensley, Roland Seiler, Harry Herr, et al.
Urologic Oncology|August 28, 2014
Assessing the quality of studies on the diagnostic accuracy of tumor markersPeter J Goebell, Ashish M Kamat, Richard J Sylvester, et al.
Urologic Oncology|November 27, 2022
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancerEmil Christensen, Alexander W Wyatt, Matthew D Galsky, et al.
Urologic Oncology|June 19, 2016
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancerEdmund C P Chedgy, James Douglas, Jonathan L Wright, et al.
NPJ Precision Oncology|July 3, 2026
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent mannerAymeric Zadoroznyj, Pontus Eriksson, Carina Bernardo, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
World Journal of Urology|January 12, 2017
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive reviewAtiqullah Aziz, Jakub Dobruch, Kees Hendricksen, et al.
The Journal of Urology|February 3, 2021
Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center StudyMarc A Furrer, Bernhard Kiss, Urs E Studer, et al.
Urologic Oncology|November 27, 2022
25 years International Bladder Cancer Network (IBCN): The past, the present, and the futureLars Dyrskjøt, Antonia Vlahou, Peter C Black, et al.
Urologic Oncology|June 4, 2021
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinomaTilman Todenhöfer, Ewan A Gibb, Roland Seiler, et al.
Oncotarget|February 20, 2016
Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2Melissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
Urologic Oncology|January 26, 2023
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1Patrick J Hensley, Roland Seiler, Harry Herr, et al.
Urologic Oncology|August 28, 2014
Assessing the quality of studies on the diagnostic accuracy of tumor markersPeter J Goebell, Ashish M Kamat, Richard J Sylvester, et al.
Urologic Oncology|November 27, 2022
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancerEmil Christensen, Alexander W Wyatt, Matthew D Galsky, et al.
Urologic Oncology|June 19, 2016
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancerEdmund C P Chedgy, James Douglas, Jonathan L Wright, et al.
NPJ Precision Oncology|July 3, 2026
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent mannerAymeric Zadoroznyj, Pontus Eriksson, Carina Bernardo, et al.
Pageof 14